CONSEQUENCES OF NIGROSTRIATAL DENERVATION ON THE GAMMA-AMINOBUTYRIC ACIDIC NEURONS OF SUBSTANTIA-NIGRA PARS RETICULATA AND SUPERIOR COLLICULUS IN PARKINSONIAN SYNDROMES
M. Vila et al., CONSEQUENCES OF NIGROSTRIATAL DENERVATION ON THE GAMMA-AMINOBUTYRIC ACIDIC NEURONS OF SUBSTANTIA-NIGRA PARS RETICULATA AND SUPERIOR COLLICULUS IN PARKINSONIAN SYNDROMES, Neurology, 46(3), 1996, pp. 802-809
To examine the effects of nigrostriatal denervation on the substantia
nigra pars reticulata (SNpr), one of the main outputs of the basal gan
glia, we used quantitative in situ hybridization to analyze the messen
ger RNA coding for Mr 67,000 glutamic acid decarboxylase (GAD(67) mRNA
) in the SNpr neurons from patients with Parkinson's disease (PD), mon
keys rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri
dine (MPTP), and their respective controls. In MPTP-intoxicated monkey
s, the expression of GAD(67) mRNA was increased in the SNpr neurons, a
nd the increase was reversed by L-dopa treatment. There were no differ
ences in the levels of GAD(67) mRNA between PD patients who had been t
reated with L-dopa and control subjects. Combined with the previously
reported increased expression of GAD(67) mRNA in the internal segment
of the pallidum of MPTP-intoxicated monkeys, these data suggest that t
he gamma-aminobutyric acidic (GABAergic) activity of the output system
of the basal ganglia is globally increased by nigrostriatal denervati
on. We also analyzed the level of GAD(67) mRNA expression in the super
ior colliculus, a structure that receives the inhibitory influence of
the GABAergic neurons of the SNpr and that is involved in eye movement
control. GAD(67) mRNA expression was reduced in both MPTP-intoxicated
monkeys, whether or not they received L-dopa therapy, and PD patients
, compared to their respective controls. This decrease may result from
the hyperactivity of the inhibitory nigrotectal pathway, but also fro
m other influences since it was not corrected by L-dopa therapy. These
changes may account for the slight ocular motor and visuospatial cogn
itive impairment occurring in PD, even after L-dopa therapy.